Full-Time

Senior Medical Writer 1

Medical Writing, Regulatory Affairs

Posted on 9/13/2025

SpringWorks Therapeutics

SpringWorks Therapeutics

201-500 employees

Clinical-stage precision medicines for cancer

Compensation Overview

$114k - $150k/yr

+ Discretionary annual bonus

Remote in USA

Remote

Occasional travel to SpringWorks offices or other locations may be required.

Category
Content & Writing (2)
,
Requirements
  • Education: Bachelor’s degree or equivalent in a scientific discipline, advanced degree preferred
  • At least 7 years’ experience in regulatory writing and knowledge of preparing documents to ICH standards.
  • Prior experience within the Pharmaceutical or CRO industry
  • Strong scientific and/or medical writing knowledge preferred
  • Ability to lead writing and compilation of clinical documents
  • Ability to influence and drive key decisions and stakeholders within a project team
  • Strong understanding of pharmaceutical industry procedures and regulations
  • Embody the SpringWorks Values to act with empathy and humility to drive a culture that takes ownership and accountability for their individual and teams’ performance.
  • Strong interpersonal communication skills to collaborate with colleagues, stakeholders, and vendors effectively and clearly in a remote hybrid work environment.
Responsibilities
  • Leads development of clinical and nonclinical documents that are submitted to regulatory authorities including but not limited to investigator brochures, study protocols, model informed consents, interim and final clinical study reports (CSR), module 2 documents, and regulatory documents such as briefing books etc.
  • Produces complex clinical or scientific documents, such as, IBs, and sections of INDs, NDAs, CTDs, and dossiers.
  • Responsible for positioning information and data for presentation of clinical, pharmacokinetic, pharmacodynamic and statistical written materials. Leads compilation of CSR appendices including data displays and clinical narratives.
  • Provides detailed medical editing review of draft and final documents prepared by other writers before internal or external distribution. This includes both copy editing and content review.
  • Ensures document content and style adheres to EMEA/FDA or other appropriate regulatory guidelines and complies with departmental SOPs and style guidelines.
  • Performs literature searches and reviews as necessary to obtain background information and provide literature references.
  • Responsible for development of medical writing SOPs and style guidelines.
  • Manages the timeline for the preparation of the documents, creating details processes, setting up kick off meetings and comment resolution meetings, owns workflows in Veeva
  • Perform other duties as assigned
SpringWorks Therapeutics

SpringWorks Therapeutics

View

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicines for patients with rare diseases and cancer. Its approach is to tailor therapies based on the genetic and molecular profile of a disease, aiming to improve treatment effectiveness and safety for underserved patient groups. The company advances drug candidates through clinical trials (such as Phase 1b and 2) and pursues partnerships with other pharmaceutical companies to acquire, develop, and commercialize therapies. Unlike broader, non-targeted programs, SpringWorks focuses on niche patient populations defined by genetic profiles and collaborates on development and commercialization, broadening access to targeted treatments. The company’s goal is to bring targeted therapies to market that address unmet medical needs in oncology and rare diseases, improving outcomes for patients with specific genetic conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck's acquisition provides global commercial scale for OGSIVEO and GOMEKLI.
  • European approval expanded mirdametinib's addressable market beyond the United States.
  • Nirogacestat combinations and pipeline programs add optionality across oncology indications.

What critics are saying

  • Post-merger integration can distract teams and slow launch execution within twelve months.
  • Ogsiveo and Gomekli concentration leaves little cushion if either franchise underperforms.
  • Merck can deprioritize earlier pipeline assets, eliminating future value beyond approved drugs.

What makes SpringWorks Therapeutics unique

  • OGSIVEO became the first FDA-approved desmoid tumor therapy in 2023.
  • GOMEKLI is the first approved therapy for NF1-PN in adults and children.
  • SpringWorks built a rare-tumor portfolio from Pfizer-origin assets and collaborations.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at SpringWorks Therapeutics who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Professional Development Budget

Flexible Work Hours

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

6%

2 year growth

5%
AllSci
Mar 17th, 2026
R1 Therapeutics launches with oversubscribed USD 77.5m Series A.

R1 Therapeutics launches with oversubscribed USD 77.5m Series A. March 17, 2026 R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A financing totaling USD 77.5 million. The company is focused on developing therapies for chronic kidney disease, the lead program targeting hyperphosphatemia in dialysis patients. R1 acquired exclusive global rights outside of Greater China to that program - AP306, a pan phosphate transporter inhibitor - via a license deal with China-based Alebund Pharmaceuticals announced alongside the Series A. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), with participation from Curie.Bio, SymBiosis, and US Renal Care. The company said proceeds will fund a global development program for AP306, including a Phase IIb study planned to begin later this year. This is R1 Therapeutics' first disclosed funding round, coinciding with the company's formal launch. AP306, previously known as EOS789, was originally discovered by Chugai Pharmaceutical Co. and subsequently licensed to Alebund Pharmaceuticals, which conducted a Phase IIa study in hemodialysis patients in China. Results from that trial, published in Kidney International Reports, showed statistically significant reductions in serum phosphate with a tolerable safety profile. AP306 is described as the only clinical-stage agent that blocks active phosphate transport via three GI-tract transporters - NaPi-2b, PiT-1, and PiT-2 - distinguishing it from phosphate binders, which inhibit passive transport and have been the standard of care for six decades. More than 40% of US dialysis patients fail to reach phosphate targets with existing therapies, which carry high pill burden and GI tolerability issues, the company said. R1 is led by co-founder, president, and CEO Krishna Polu, M.D., a nephrologist with more than 20 years of biopharmaceutical experience. Co-founder L. Mary Smith, Ph.D., who previously served as chief development officer at SpringWorks Therapeutics, joins as chief operating officer. Your email address will not be published. Required fields are marked *

PharmiWeb.com
May 27th, 2025
Springworks Therapeutics Receives Positive Chmp Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With Nf1-Pn

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN. – If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –. – Decision from European Commission expected in the third quarter of 2025 –

Merck Group
May 5th, 2025
agreement-to-acquire-springworks

Merck KGaA, Darmstadt, Germany, and SpringWorks Therapeutics, have entered into a definitive agreement for us to acquire SpringWorks.

MedCity News
Apr 28th, 2025
Merck KGaA's Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition

When SpringWorks went public in 2019, the biotech priced its shares at $18 each.

IT Juzi
Apr 28th, 2025
Merck Acquires SpringWorks for $3.9B

German Merck Group has announced a $3.9 billion acquisition agreement with U.S. biopharmaceutical company SpringWorks Therapeutics. This acquisition aims to enhance Merck's cancer drug business. SpringWorks Therapeutics, a biopharmaceutical developer, has obtained four potential new drugs in clinical stages from Pfizer.

INACTIVE